Magnetization Transfer BOOST Noncontrast Angiography Improves Pulmonary Vein Imaging in Adults With Congenital Heart Disease.
Humans
Adult
Female
Adolescent
Young Adult
Middle Aged
Male
Pulmonary Veins
/ diagnostic imaging
Prospective Studies
Magnetic Resonance Angiography
/ methods
Heart Defects, Congenital
/ diagnostic imaging
Magnetic Resonance Imaging
Contrast Media
Imaging, Three-Dimensional
/ methods
Reproducibility of Results
3D whole heart imaging
MTC-BOOST
congenital heart disease
magnetization Transfer
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
14
05
2022
received:
16
01
2022
accepted:
17
05
2022
pubmed:
2
6
2022
medline:
20
1
2023
entrez:
1
6
2022
Statut:
ppublish
Résumé
Cardiac MRI plays an important role in the diagnosis and follow-up of patients with congenital heart disease (CHD). Gadolinium-based contrast agents are often needed to overcome flow-related and off-resonance artifacts that can impair the quality of conventional noncontrast 3D imaging. As serial imaging is often required in CHD, the development of robust noncontrast 3D MRI techniques is desirable. To assess the clinical utility of noncontrast enhanced magnetization transfer and inversion recovery prepared 3D free-breathing sequence (MTC-BOOST) compared to conventional 3D whole heart imaging in patients with CHD. Prospective, image quality. A total of 27 adult patients (44% female, mean age 30.9 ± 14.8 years) with CHD. A 1.5 T; free-breathing 3D MTC-BOOST sequence. MTC-BOOST was compared to diaphragmatic navigator-gated, noncontrast T2 prepared 3D whole-heart imaging sequence (T2prep-3DWH) for comparison of vessel dimensions, lumen-to-myocardium contrast ratio (CR), and image quality (vessel wall sharpness and presence and type of artifacts) assessed by two experienced cardiologists on a 5-point scale. Mann-Whitney test, paired Wilcoxon signed-rank test, Bland-Altman plots. P < 0.05 was considered statistically significant. MTC-BOOST significantly improved image quality and CR of the right-sided pulmonary veins (PV): (CR: right upper PV 1.06 ± 0.50 vs. 0.58 ± 0.74; right lower PV 1.32 ± 0.38 vs. 0.81 ± 0.73) compared to conventional T2prep-3DWH imaging where the PVs were not visualized in some cases due to off-resonance effects. MTC-BOOST demonstrated resistance to degradation of luminal signal (assessed by CR) secondary to accelerated or turbulent flow conditions. T2prep-3DWH had higher image quality scores than MTC-BOOST for the aorta and coronary arteries; however, great vessel dimensions derived from MTC-BOOST showed excellent agreement with standard T2prep-3DWH imaging. MTC-BOOST allows for improved contrast-free imaging of pulmonary veins and regions characterized by accelerated or turbulent blood flow compared to standard T2prep-3DWH imaging, with excellent agreement of great vessel dimensions. 1 TECHNICAL EFFICACY: Stage 2.
Sections du résumé
BACKGROUND
Cardiac MRI plays an important role in the diagnosis and follow-up of patients with congenital heart disease (CHD). Gadolinium-based contrast agents are often needed to overcome flow-related and off-resonance artifacts that can impair the quality of conventional noncontrast 3D imaging. As serial imaging is often required in CHD, the development of robust noncontrast 3D MRI techniques is desirable.
PURPOSE
To assess the clinical utility of noncontrast enhanced magnetization transfer and inversion recovery prepared 3D free-breathing sequence (MTC-BOOST) compared to conventional 3D whole heart imaging in patients with CHD.
STUDY TYPE
Prospective, image quality.
POPULATION
A total of 27 adult patients (44% female, mean age 30.9 ± 14.8 years) with CHD.
FIELD STRENGTH/SEQUENCE
A 1.5 T; free-breathing 3D MTC-BOOST sequence.
ASSESSMENT
MTC-BOOST was compared to diaphragmatic navigator-gated, noncontrast T2 prepared 3D whole-heart imaging sequence (T2prep-3DWH) for comparison of vessel dimensions, lumen-to-myocardium contrast ratio (CR), and image quality (vessel wall sharpness and presence and type of artifacts) assessed by two experienced cardiologists on a 5-point scale.
STATISTICAL TESTS
Mann-Whitney test, paired Wilcoxon signed-rank test, Bland-Altman plots. P < 0.05 was considered statistically significant.
RESULTS
MTC-BOOST significantly improved image quality and CR of the right-sided pulmonary veins (PV): (CR: right upper PV 1.06 ± 0.50 vs. 0.58 ± 0.74; right lower PV 1.32 ± 0.38 vs. 0.81 ± 0.73) compared to conventional T2prep-3DWH imaging where the PVs were not visualized in some cases due to off-resonance effects. MTC-BOOST demonstrated resistance to degradation of luminal signal (assessed by CR) secondary to accelerated or turbulent flow conditions. T2prep-3DWH had higher image quality scores than MTC-BOOST for the aorta and coronary arteries; however, great vessel dimensions derived from MTC-BOOST showed excellent agreement with standard T2prep-3DWH imaging.
DATA CONCLUSION
MTC-BOOST allows for improved contrast-free imaging of pulmonary veins and regions characterized by accelerated or turbulent blood flow compared to standard T2prep-3DWH imaging, with excellent agreement of great vessel dimensions.
EVIDENCE LEVEL
1 TECHNICAL EFFICACY: Stage 2.
Identifiants
pubmed: 35642573
doi: 10.1002/jmri.28280
pmc: PMC10084321
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-531Subventions
Organisme : Wellcome Trust
ID : WT 203148/Z/16/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/59/33955
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.
Références
Magn Reson Med. 2011 Jul;66(1):180-6
pubmed: 21360738
Comput Methods Programs Biomed. 2010 Jun;98(3):278-84
pubmed: 19818524
Magn Reson Med. 2018 Mar;79(3):1460-1472
pubmed: 28722267
J Magn Reson Imaging. 2010 Nov;32(5):1255-61
pubmed: 21031533
Circulation. 2002 Jul 23;106(4):473-8
pubmed: 12135948
J Cardiovasc Magn Reson. 2013 Jun 13;15:51
pubmed: 23763839
Magn Reson Med. 2014 Sep;72(3):779-85
pubmed: 24151231
Phys Med Biol. 1985 Apr;30(4):341-4
pubmed: 4001160
AJR Am J Roentgenol. 1988 Nov;151(5):1025-30
pubmed: 3263000
J Cardiovasc Magn Reson. 2014 Nov 22;16:91
pubmed: 25416082
J Cardiovasc Magn Reson. 2018 Nov 26;20(1):76
pubmed: 30474554
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):281-97
pubmed: 25712078
Circulation. 1999 Jun 22;99(24):3139-48
pubmed: 10377077
Int J Epidemiol. 2019 Apr 1;48(2):455-463
pubmed: 30783674
Magn Reson Med. 2005 Nov;54(5):1273-80
pubmed: 16155887
J Magn Reson Imaging. 2022 Jan;55(1):61-80
pubmed: 33078512
J Magn Reson Imaging. 2015 Mar;41(3):738-46
pubmed: 24573992
Int J Cardiovasc Imaging. 2007 Dec;23(6):747-56
pubmed: 17285264
J Magn Reson Imaging. 2010 Jan;31(1):177-84
pubmed: 20027585
Radiology. 2017 Nov;285(2):546-554
pubmed: 28653860
Heart. 2018 Oct;104(20):1643-1644
pubmed: 29666177
Front Pediatr. 2017 Feb 27;5:36
pubmed: 28289674
Circulation. 2004 Jul 13;110(2):163-9
pubmed: 15210590
Magn Reson Med. 2017 May;77(5):1894-1908
pubmed: 27221073
Magn Reson Med. 2019 Feb;81(2):1066-1079
pubmed: 30230609
Magn Reson Med. 2012 Feb;67(2):437-45
pubmed: 21656563
Magn Reson Med. 2002 Feb;47(2):372-83
pubmed: 11810682
J Am Coll Cardiol. 2002 Jan 16;39(2):335-41
pubmed: 11788228
Magn Reson Med. 2013 Feb;69(2):486-94
pubmed: 22529009